You are here : Version anglaise > Research > NeuroMyoGene Institute (INMG)
-
Partager cette page
NeuroMyoGene Institute (INMG)
The NeuroMyoGène Institute is a novel institute dedicated to the study of the nervous and muscular systems. It was created in 2016 in Lyon at the heart of a dense hospital network and of one of the biggest medical universities in France.
The INMG goal is to unravel fundamental aspects of the cell biology of the muscle and nervous system from development to aging under normal and pathological conditions. Using a variety of invertebrate and vertebrate model systems, the INMG is conducting an integrated multidisciplinary research from gene to physiological functions. One of its priorities is to develop relevant strategies to decipher multiple forms of neuromuscular diseases, identify new therapeutic targets and foster novel strategies for innovative treatments. The INMG benefits from the integration of cutting-edge fundamental research teams and renowned clinicians, including the directors of three reference centers for neuromuscular diseases, paraneoplastic syndromes and genetic cardiac rhythm diseases.
The INMG is a consortium of three research organizations: the CNRS, the INSERM and the University Claude Bernard in Lyon. The Institute also gets strong support from the French Association against Myopathies (AFM). It gathers 14 individual research teams and about 190 people. In January 2018, the fourteen INMG teams have moved into newly renovated laboratory and office space on the Rockefeller Medical school campus.
The INMG goal is to unravel fundamental aspects of the cell biology of the muscle and nervous system from development to aging under normal and pathological conditions. Using a variety of invertebrate and vertebrate model systems, the INMG is conducting an integrated multidisciplinary research from gene to physiological functions. One of its priorities is to develop relevant strategies to decipher multiple forms of neuromuscular diseases, identify new therapeutic targets and foster novel strategies for innovative treatments. The INMG benefits from the integration of cutting-edge fundamental research teams and renowned clinicians, including the directors of three reference centers for neuromuscular diseases, paraneoplastic syndromes and genetic cardiac rhythm diseases.
The INMG is a consortium of three research organizations: the CNRS, the INSERM and the University Claude Bernard in Lyon. The Institute also gets strong support from the French Association against Myopathies (AFM). It gathers 14 individual research teams and about 190 people. In January 2018, the fourteen INMG teams have moved into newly renovated laboratory and office space on the Rockefeller Medical school campus.